Ulrike Mody-Graefe
Ingelheim Am Rhein, RP 55216, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Journal: Clinical diabetes and endocrinology
Published: October 30, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Journal: Diabetes, obesity & metabolism
Published: October 22, 2015
Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
Journal: Journal of diabetes investigation
Published: August 21, 2015
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
Journal: Clinical pharmacokinetics
Published: February 01, 2015
Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254.
Journal: Clinical pharmacology in drug development
Published: July 23, 2013
Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
Journal: American journal of therapeutics
Published: February 16, 2013
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: July 19, 2012
Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Journal: British journal of clinical pharmacology
Published: May 30, 2012
Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Journal: Clinical pharmacokinetics
Published: May 10, 2012
The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
Journal: International journal of clinical pharmacology and therapeutics
Published: May 01, 2012
Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Journal: British journal of clinical pharmacology
Published: January 17, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026